Compare ELTX & ETON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELTX | ETON |
|---|---|---|
| Founded | 2011 | 2017 |
| Country | United States | United States |
| Employees | N/A | 44 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 185.4M | 872.7M |
| IPO Year | 2014 | 2018 |
| Metric | ELTX | ETON |
|---|---|---|
| Price | $11.34 | $30.21 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $18.00 | ★ $39.33 |
| AVG Volume (30 Days) | 123.3K | ★ 420.7K |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 39.29 | N/A |
| EPS | N/A | ★ 0.05 |
| Revenue | $2,301,000.00 | ★ $79,950,000.00 |
| Revenue This Year | N/A | $40.90 |
| Revenue Next Year | N/A | $47.23 |
| P/E Ratio | ★ N/A | $638.20 |
| Revenue Growth | N/A | ★ 104.94 |
| 52 Week Low | $6.92 | $13.09 |
| 52 Week High | $14.93 | $35.66 |
| Indicator | ELTX | ETON |
|---|---|---|
| Relative Strength Index (RSI) | 55.50 | 51.68 |
| Support Level | $9.63 | $16.23 |
| Resistance Level | $11.47 | $32.31 |
| Average True Range (ATR) | 0.98 | 1.92 |
| MACD | 0.10 | -0.31 |
| Stochastic Oscillator | 59.84 | 28.79 |
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has eight commercial rare disease products, INCRELEX, ALKINDI SPRINKLE, KHINDIVITM, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous and Nitisinone. It also has five additional product candidates in late-stage development: ET-600, Amglidia, ET-700, ET-800 and ZENEO hydrocortisone autoinjector.